Novel vaccine strategy to treat high risk prostate cancer patients
| Reference number | |
| Coordinator | IMMUNEED AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | July 2017 - December 2017 |
| Status | Completed |
Purpose and goal
The overall objective of the project is to continue into clinical development with MTTE-001, a new therapeutic vaccine for patients with prostate cancer who is expected to have a high risk of spreading in their disease. The aim of the Phase 1 study was to develop a development plan for the first clinical studies and to attract potential investors. It also includes identifying companies that need the company´s TET platform for other peptides. During the project, the company has developed a development plan and initiated discussions with companies that are interested in TET.
Expected results and effects
The successful implementation of the overall innovation project will enable Immuneed to propose a new treatment option for prostate cancer. It will also facilitate a dialogue with one or more potential investors or partners. During the project, a further understanding has been gained on how MTTE-001 has the potential to change and improve the treatment of patients diagnosed with localized prostate cancer with an intermediate and high risk of spreading in their disease.
Planned approach and implementation
An early development plan has been developed that covers both clinical and CMC parts. We have developed a study synopsis in dialogue with urologists and experts in clinical drug development. We have also talked with Clinical CROn to gain an understanding of study length and costs. We have discussed the manufacturing and up-scaling of our vaccine, and identified some limitations and opportunities for development that exist. We have also conducted a market investigation to understand the number of potential patients in the different patient segments.